Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Celldex Therapeutics Inc. shares valued at $608,315 were sold by Martin Samuel Bates on Jun 14 ’24. At $35.42 per share, Martin Samuel Bates sold 17,172 shares. The insider’s holdings dropped to 28,125 shares worth approximately $1.18 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Crowley Elizabeth sold 30,000 shares, netting a total of over 1,045,962 in proceeds. Following the sale of shares at $34.87 each, the insider now holds 9,074 shares.
Before that, Crowley Elizabeth had sold 15,000 shares from its account. In a trade valued at $525,873, the SR. VP & CPDO traded Celldex Therapeutics Inc. shares for $35.06 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $0.38 million.
As published in their initiating research note from Stifel on June 18, 2024, Celldex Therapeutics Inc. [CLDX] has been a Buy and the price target has been revised to $58. Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid June. As of December 20, 2023, TD Cowen has initiated its “an Outperform” rating for CLDX. Earlier on November 10, 2023, Wells Fargo upgraded its rating. Their new recommendation was “an Equal weight” for CLDX stock which previously was a “an Underweight”.
Analyzing CLDX Stock Performance
During the last five days, there has been a surge of approximately 0.50%. Over the course of the year, Celldex Therapeutics Inc. shares have jumped approximately 5.52%. Shares of the company reached a 52-week high of $53.18 on 03/04/24 and a 52-week low of $31.40 on 08/14/24. A 50-day SMA is recorded $38.36, while a 200-day SMA reached $38.66. Nevertheless, trading volume fell to 1.08 million shares from 1.0 million shares the previous day.
Support And Resistance Levels for Celldex Therapeutics Inc. (CLDX)
According to the 24-hour chart, there is a support level at 41.17, which, if violated, would cause prices to drop to 40.49. In the upper region, resistance lies at 42.86. The next price resistance is at 43.86. RSI (Relative Strength Index) is 56.29 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.33, which suggests the price will decrease in the coming days. Percent R is at 50.77%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
#####
#####
